Childhood central nervous system mixed germ cell tumor
disease diseaseOn this page
Also known as Central nervous system Mixed germ cell tumorCentral nervous system Mixed germ cell tumourchildhood mixed germ cell tumor of central nervous systemchildhood mixed germ cell tumour of central nervous systemmixed germ cell tumor of central nervous system of childhoodmixed germ cell tumour of central nervous system of childhoodpaediatric mixed germ cell tumour of central nervous systempediatric mixed germ cell tumor of central nervous system
Summary
Childhood central nervous system mixed germ cell tumor (MONDO:0004257) is a cancer and 6 clinical trials. Top therapeutic interventions include leucovorin and pazopanib hydrochloride. A subtype of childhood central nervous system germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | childhood central nervous system mixed germ cell tumor |
| Mondo ID | MONDO:0004257 |
| DOID | DOID:7516 |
| NCIT | C27403 |
| UMLS | C1332956 |
| MedGen | 232346 |
| GARD | 0023902 |
| Is cancer (heuristic) | yes |
Also known as: Central nervous system Mixed germ cell tumor · Central nervous system Mixed germ cell tumour · childhood mixed germ cell tumor of central nervous system · childhood mixed germ cell tumour of central nervous system · mixed germ cell tumor of central nervous system of childhood · mixed germ cell tumour of central nervous system of childhood · paediatric mixed germ cell tumour of central nervous system · pediatric mixed germ cell tumor of central nervous system
Disease family
This is a subtype of childhood central nervous system germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › central nervous system germ cell tumor › childhood central nervous system germ cell tumor › childhood central nervous system mixed germ cell tumor
Related subtypes (7): central nervous system endodermal sinus tumor, childhood central nervous system mature teratoma, pediatric CNS choriocarcinoma, childhood central nervous system immature teratoma, childhood central nervous system embryonal carcinoma, childhood germ cell brain tumor, childhood central nervous system germinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 6 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00281944 | PHASE1 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors |
| NCT00387920 | PHASE1 | COMPLETED | Sunitinib in Treating Young Patients With Refractory Solid Tumors |
| NCT00929903 | PHASE1 | COMPLETED | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment |
| NCT00994500 | PHASE1 | COMPLETED | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
| NCT01076530 | PHASE1 | COMPLETED | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LEUCOVORIN | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| CHEMBL3109278 | 0 | 1 |
Related Atlas pages
- Drugs: Pazopanib, CHEMBL3109278